American Society of Ketamine
Physicians, Psychotherapists & Practitioners
Who Is ASKP3?
The American Society of Ketamine Physicians, Psychotherapists, and Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
0
+
Members
Active members of ASKP3 worldwide.
0
+
Countries
Locations of our active members globally.
ASKP3 Past Public Events
ASKP3 Standards of Practice and Ethics Statement 2020
ASKP3 Vision Statement:
An interdisciplinary community of collaborative practitioners led by experts providing education and ethical standards for patient care with ketamine and emerging treatments.
ASKP3 Mission Statement
Our mission is to advance the treatment of mental and physical health through the use of ketamine by:
- Establishing scientific, ethical and transparent standards among practitioners
- Advancing the quality of care through the furthering of knowledge, the exchange of ideas, and research
- Fostering multidisciplinary collaboration to improve patient outcomes
- Educating the clinical communities about all aspects of this treatment modality
- Building awareness and understanding among the general population, legislators, regulators and payers
- Welcoming relationships that support the development of other psychedelic therapies
Basics of Administration
The American Society of Ketamine Physicians, Psychotherapists, & Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
ASKP3 serves as a forum to discuss the use of therapeutic ketamine for Non-Anesthetic Indications (KNAI). KNAI is fundamentally different than the traditional use of ketamine as an anesthetic.
We recognize that therapeutic ketamine is being administered by clinicians through different routes of delivery (IV, IM, IN, PO, etc.). ASKP3 does not endorse any particular route of delivery however we feel it is important that the combination of delivery and dose do not cross over from KNAI to moderate sedation unless the provider and clinical setting are appropriate for that treatment.
Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment – examples include Unipolar Major Depression, Bipolar Depression, PTSD, OCD, Fibromyalgia, CRPS and other forms of chronic pain.
A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart. The patient’s medications and allergies should also be documented to reduce reasonable risk of medication interaction and side effects.
Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.
Practitioners should have their established protocol easily available to the public. The use of “secret formulations” and “proprietary blends” runs counter to the concept of evidence-based medicine.
The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic. An appropriately licensed and qualified medical provider should be present during the administration as well.
Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.
We do not support the use of medically unsupervised parenterally administered ketamine.
